A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

The study results revealed glycemic improvements using Omnipod 5 compared with insulin injections or pump therapy treatments in adults with type 2 diabetes. The outcome demonstrated significant ...

Insulet continues to see adoption of its Omnipod 5 pump—the device that represents Insulet's entrance into hybrid closed-loop technology that makes life easier by automating insulin delivery ...

US-based Insulet has unveiled positive results from a study investigating its Omnipod 5 system compared to insulin pump therapy with continuous glucose monitoring (CGM). Insulet’s Omnipod 5 is a ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes ...

Insulet's Omnipod 5 device is the first such system to be ... to ease investor concerns about the potential hit on its insulin pump sales, given the soaring demand for the newer diabetes and ...

Perspective from Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 ...

Curious as to what was inside, [Ido Roseman] tore down an Omnipod Dash and took some pictures ... communicate wirelessly with a control system, and pump insulin through the cannula as needed.

The automated insulin delivery ... U.S. Omnipod revenue increased 12.4% to $443.7 million, and International Omnipod revenue rose to $142.0 million, an increase of 33.5%, or 33.1%, in constant ...